E2F1

E2F1
Name	E2F1
Uniprot	P20226
Organism	Homo sapiens
Chromosome	20q11.2

E2F1 E2F1 is a human transcription factor central to cell cycle control, DNA damage response, and apoptosis. Prominent in studies involving Harvard University, Cold Spring Harbor Laboratory, National Institutes of Health, Max Planck Society, and Stanford University, E2F1 has been examined alongside factors such as TP53, RB1, MYC, ATM, and CHK2 in contexts ranging from oncology at the American Association for Cancer Research to structural biology at the European Molecular Biology Laboratory. Its dysregulation has implications in clinical research at institutions like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Mayo Clinic.

Introduction

E2F1 was identified through studies at Cold Spring Harbor Laboratory and characterized in parallel with other E2F family members by investigators at University of California, San Diego, Yale University, and Salk Institute. Initially linked to transcriptional activation of S-phase genes, E2F1 functions have been contextualized in research programs at National Cancer Institute and in large-scale genomics efforts at Broad Institute and Wellcome Sanger Institute. The protein has been studied using model systems established at University of Cambridge, MIT, UCSF, and Johns Hopkins University.

Structure and Molecular Features

E2F1 contains a conserved DNA-binding domain characterized in structural studies at European Synchrotron Radiation Facility and Argonne National Laboratory, and a marked-box implicated in dimerization with DP family proteins identified at Max Planck Institute for Biophysical Chemistry. Crystallography and NMR work from groups at Yale University, University of Oxford, and EMBL-EBI elucidated interfaces relevant to interactions with RB1 and complexes analyzed at Cold Spring Harbor Laboratory and Stanford University Medical Center. Sequence motifs and domains are cataloged in databases maintained by UniProt, NCBI, and Ensembl, and comparative genomics across species in projects at European Bioinformatics Institute and Broad Institute highlight conserved residues.

Regulation and Post-translational Modifications

Phosphorylation of E2F1 by kinases such as ATM, ATR, CDK2, and CHK2 was demonstrated in laboratories at University of Pennsylvania, University of Texas MD Anderson Cancer Center, and Harvard Medical School, linking DNA damage signaling to transcriptional outcomes observed in studies by teams at Cold Spring Harbor Laboratory and Salk Institute for Biological Studies. Ubiquitination and proteasomal degradation involving ligases studied at EMBL and Institute of Cancer Research modulate E2F1 stability, while acetylation by enzymes characterized at Rockefeller University and Max Planck Institute alters activity. SUMOylation and methylation events reported from University of California, Berkeley and Karolinska Institutet further diversify regulatory control.

Biological Functions and Pathways

E2F1 controls expression of genes required for DNA replication and S-phase entry, connecting to pathways investigated by consortia at Human Genome Project, Cancer Genome Atlas, and ENCODE Project. It contributes to apoptosis signaling in networks overlapping with TP53, BAX, and CASP3 as studied at Memorial Sloan Kettering Cancer Center and Mount Sinai Hospital. Roles in DNA repair involve coordination with BRCA1, RAD51, and MRE11 complexes analyzed at Cold Spring Harbor Laboratory and European Molecular Biology Laboratory, while metabolic regulation intersections have been probed by teams at MIT, Imperial College London, and University of Toronto.

Role in Cancer and Disease

Aberrant E2F1 activity is implicated in tumorigenesis, with clinical correlations reported by researchers at Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Mayo Clinic across malignancies such as breast cancer, lung cancer, colorectal cancer, and glioblastoma. Genetic and epigenetic alterations affecting E2F1 pathways emerge in datasets from The Cancer Genome Atlas and International Cancer Genome Consortium and have spurred therapeutic investigations at Roche, Novartis, and Pfizer. Links to syndromes involving cell cycle defects have been described in clinical centers including Cleveland Clinic and Johns Hopkins Hospital.

Interactions and Protein Partners

E2F1 forms functional partnerships with DP family proteins identified in biochemical work at Cold Spring Harbor Laboratory and Yale University, and is regulated by interactions with RB1, HDAC1, CBP, p300, and ubiquitin ligases characterized at EMBL-EBI and Max Planck Institute for Molecular Genetics. Cross-talk with signaling molecules such as ATM, CHK2, CDK2, MYC, and TP53 has been delineated by collaborative projects at National Institutes of Health and European Molecular Biology Laboratory. Large-scale interaction maps including E2F1 were generated by efforts at BioGRID, STRING Consortium, and IntAct.

Research Tools and Experimental Studies

Experimental investigation of E2F1 uses reagents and platforms from Addgene, CRISPR Consortium, Thermo Fisher Scientific, and Illumina; model organisms and cell lines used in studies include resources from Jackson Laboratory, ATCC, and repositories at European Collection of Authenticated Cell Cultures. Structural and functional assays have been reported by groups at EMBL, Argonne National Laboratory, and Diamond Light Source, while clinical translational studies and trials have been coordinated through networks such as NCI Cooperative Trials Program and consortia affiliated with European Organisation for Research and Treatment of Cancer.

Category:Transcription factors